The results showed HER2 amplifications in patients with various tumor types, including endometrial (5.3%), bladder (5.2%), biliary or gallbladder (4.9%), salivary (4.7%), and colorectal cancer (3.6%). This evidence concerns the gene ERBB2 and colorectal cancer.